As the only FDA approved agent for treating catheter occlusions, the current shortage of Alteplase has professionals in the acute and critical care arena reeling. The occurrence of catheter occlusion is a common, yet serious complication when dealing with patients who have central venous catheters. The occlusion typically occurs as a result of thrombosis, and this is where the thrombolytic medication Alteplase acts as an efficacious and lifesaving treatment. Prior uses of treatments like urokinase and streptokinase to remedy CVC occlusions have now been ruled out by the FDA as solutions, due to adverse effects like high rates of infection and anaphylaxis. With Alteplase now the only effectual, viable and approved option for remedying catheter occlusions, the shortage of this vital drug is frightening.
Alteplase is not only effective for solving the catheter occlusion dilemmas, it is also a tissue plasminogen activator, or t-PA, which is essential for breaking down blood clots. On March 13, 2013 the American Heart Association presented revised guidelines for stroke treatment, touting the use of Alteplase in patients who had stroke symptoms. The AHA updated guidelines suggest that patients receive treatment with Alteplase for four and a half hours after the onset of stroke signs and symptoms. While the previous indication for the use of Alteplase in stroke emergent patients did promote the specific use of Alteplase, the suggested timeframe was to continue treatment for only three hours after the symptoms of a stroke. Physicians across the United States expressed their satisfaction with the AHA’s off- label recommendation for Alteplase, citing the ability for them to now treat patients to ensure that all possible help was offered. Patients who are administered the intravenous medication Alteplase are quite commonplace in the average ER. To receive Alteplase a patient must be at least 18 years of age and have a diagnosis of an ischemic stroke. The administration of Alteplase is applicable if the patient has had an onset of symptoms for less than three hours’ time. The urgency for the use of Alteplase is apparent in a variety of medical settings, ranging from remedying CVC occlusions to mitigating strokes.
If you operate in the compounding industry, or are a research center or development laboratory, LGM Pharma can supply Alteplase for your company’s needs. LGM Pharma provides Alteplase, CAS number 105857-23-6 for research and development purposes. Clients can be assured of quality API products and continuous support throughout the R&D process.
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.